Filing Details

Accession Number:
0001609351-17-000120
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-11-20 17:14:58
Reporting Period:
2017-11-16
Accepted Time:
2017-11-20 17:14:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1609351 Spark Therapeutics Inc. ONCE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1438421 W Stephen Webster C/O Spark Therapeutics, Inc.
3737 Market Street, Suite 1300
Philadelphia PA 19104
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-11-16 10,000 $3.45 12,500 No 4 M Direct
Common Stock Disposition 2017-11-16 10,000 $70.14 2,500 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2017-11-16 10,000 $0.00 10,000 $3.45
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
106,015 2024-07-07 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2017, as amended.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.95, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
  3. This option was granted on July 7, 2014 and vests over four years, with 25% of the shares underlying the option vesting on July 7, 2015, and the remainder vesting quarterly thereafter.